Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer | Zendy

Xin Shelley Wang | Zendy; Qiuling Shi | Zendy; Patrick M. Dougherty | Zendy; Cathy Eng | Zendy; Tito R. Mendoza | Zendy; Loretta A. Williams | Zendy; David R. Fogelman | Zendy; Charles S. Cleeland | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer

Author(s) -

Xin Shelley Wang,

Qiuling Shi,

Patrick M. Dougherty,

Cathy Eng,

Tito R. Mendoza,

Loretta A. Williams,

David R. Fogelman,

Charles S. Cleeland

Publication year - 2016

Publication title -

oncology

Language(s) - English

Resource type - Journals

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000443377

Subject(s) - oxaliplatin , medicine , chemotherapy induced peripheral neuropathy , colorectal cancer , peripheral neuropathy , chemotherapy , gastroenterology , cancer , oncology , endocrinology , diabetes mellitus

We examined the emergence of chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting toxicity of oxaliplatin, over the course of oxaliplatin-based chemotherapy for colorectal cancer (CRC). Predicting which patients will likely develop CIPN is an ongoing clinical challenge.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research